Biotech rocks, $RVXCF in Phase III Trial for Di
Post# of 98041
Trial for Diabetes patients at high risk of a Major Adverse Cardiac Event slated to end latter this year. FDA and EMA are on board, if Apabetalone drug is approved this could be a blockbuster.